Session » Abstracts: Epidemiology & Public Health III

Date: Wednesday, November 15, 2023

Time: 9:00AM-10:30AM

Meeting: ACR Convergence 2023

9:00AM-10:30AM: Abstract Number: 2567

An Extended Interval Between mRNA COVID-19 Booster Vaccinations Is Associated with an Increased Humoral Immune Response in Patients with Inflammatory Rheumatic Diseases

9:00AM-10:30AM: Abstract Number: 2563

Causal Associations Between Gut Microbiota and Rheumatic Diseases: A Mendelian Randomization Study

9:00AM-10:30AM: Abstract Number: 2566

Comparisons of the Risk of Serious Infections Associated with the Different Classes of Targeted Therapies Used in Psoriatic Arthritis Patients: A Nationwide Cohort Study from the French Health Insurance Database

9:00AM-10:30AM: Abstract Number: 2568

First Breakthrough COVID-19 Infection Following Two SARS-CoV-2 Vaccinations Among Primary Systemic Vasculitis Patients

9:00AM-10:30AM: Abstract Number: 2564

The Effectiveness of a Fourth Dose of COVID-19 mRNA Vaccine in Patients with Systemic Autoimmune Rheumatic Diseases Using Immunomodulators: An Emulated Target Trial

9:00AM-10:30AM: Abstract Number: 2565

The Problem of Pain in Rheumatology: A Population-based Study of Annual Trends in Pain Management Modalities in Patients with Autoimmune Rheumatic Diseases in the United States, 2007-2021

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].